Research Clinics

Yale Depression Research Program |

A Phase IIa, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients
[HIC#02823]

This study is designed to explore the potential rapid and transient anti-depressant effect of a novel drug. This study requires a one-time infusion of study drug or placebo and 4 nights on an inpatient unit (Clinical Neuroscience Research Unit of Connecticut Mental Health Center) and subjects will be compensated for their time and inconvenience. In order to be eligible, subjects must be diagnosed with treatment-resistant depression which for our purposes is defined as having had two sufficient courses of anti-depressant medications which failed to provide relief from depressive symptoms. If currently on anti-depressant medications, there is a brief washout period before the treatment period and subjects will be closely monitored during this period by the study team. If clinically necessary, subjects can stay on the inpatient unit during the washout period. After the study has been completed, the study team will work with subjects to determine what next steps will be taken to help alleviate depressive symptoms. This may or may not included anti-depressant medication and subjects’ desires will be considered and respected.

Copyright ©2005. Yale University School of Medicine, Psychiatry Department. All rights reserved.
Comments or suggestions to the site editor.

Home URL: http://info.med.yale.edu/ysm